Document is current

Article History

Received: 4 December 2024

Accepted: 11 February 2025

First Online: 26 February 2025

Declarations

:

: The study protocol was registered in Clinicaltrials.gov (NCT05847998). The institutional review board, Comité de protection des personnes Sud-Méditerranée I (IRB: N° ID-RCB 2021-A02595-36) approved the study protocol. In agreement with the French law n° 2012 − 300 of March 5, 2012, informed consent of the patients (or their support person when the patient could not be informed) was systematically obtained before the inclusion.

: Not applicable.

: DiCART™ is a full automatized handled device to assess capillary refill time. Its agreement with clinical evaluation of capillary refill time is poor. Its reproducibility is lower than clinical evaluation of capillary refill time.

: MJL is cofounder and shareholder of the DiCARTECH company that has been created to build and sell a device that measures capillary refill time. AD, TA, JF, MR have no conflicts of interest related to the study to declare.